Castle Biosciences Q1 revenue $73M (+74% YoY); raises FY2024 guidance to $255-265M

CASTLE BIOSCIENCES INC

2024-Q1 EPS reported -$0.09 revenue$72,974,000

Q1 revenue $73.0M (+74% YoY); adjusted revenue $71.3M (+64% YoY).
Net loss narrowed to $2.5M from $29.2M; adjusted EBITDA improved to $10.5M from -$15.1M.
Total test reports +40% to 20,888; TissueCypher +148%, IDgenetix +90%.
FY2024 revenue guidance raised to $255-265M from prior $235-240M.
Cash & marketable securities $239.2M; gross margin 78% (adj. 81%).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

CASTLE BIOSCIENCES INC reported the first quarter ended March 31, 2024 results: revenue $73.0 million, net income Net loss... was $2.5 million. Guidance raised.

Period: the first quarter ended March 31, 2024
Revenue: $73.0 million
Net income: Net loss... was $2.5 million
Guidance: raised
Result: reported results

Exact text from the filing

such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports First Quarter 2024 Results Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $ 255-265 million from $235-240 million Conference call and webcast today at 4:30

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-24-000059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.